Dr Mummery is a consultant neurologist at the National Hospital for Neurology and Neurosurgery. Cath us Chair of the NIHR Dementia Translational Research Collaboration, building a national unified trials network for early phase clinical trials and working with the Dementia Mission to accelerate and enhance dementia translational research in novel treatments. She is also Head of Clinical Trials at the Dementia Research Centre, University College London. Over the past 17 years, Cath has been a chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer’s disease (AD) and genetic forms of AD and frontotemporal dementia, including immunotherapies against amyloid and tau, and novel mechanisms in first-in-human trials including checkpoint inhibitors, gene silencing and AAV genetic therapies. As clinical lead for the UCL Neurogenetic Therapies Programme, Cath leads a programme of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer’s, but that we can deliver them promptly, safely and equitably.